Clinical Trial Update: Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating bezlotoxumab in addition to standard vancomycin for multi-recurrent Clostridium difficile infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• Bezlotoxumab (BEZLO) (bezlotoxumab)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Clostridium Difficile Infection Recurrence | Phase 4 | Status: COMPLETED